Novartis to amass Avidity Biosciences for about $12 billion - Reuters

Novartis to amass Avidity Biosciences for about $12 billion Reuters
Novartis to purchase U.S. biotech agency Avidity Biosciences for about $12 billion in money CNBC
Novartis agrees to amass Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis
Novartis Mentioned to Close to at Least $70-Per-Share Deal for Avidity Bloomberg.com
Novartis to purchase RNA-focused Avidity in $12 billion deal statnews.com